» Articles » PMID: 35179622

MDMA and Memory, Addiction, and Depression: Dose-effect Analysis

Overview
Specialty Pharmacology
Date 2022 Feb 18
PMID 35179622
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: ±3,4-Methylenedioxymethamphetamine (MDMA) is a recreational drug that shows substantial promise as a psychotherapeutic agent. Still, there is some concern regarding its behavioral toxicity, and its dose-effect relationship is poorly understood. We previously explored the role of dose in the cognitive effects of MDMA in a systematic review of existing literature and found no evidence in animals that MDMA impairs memory at low doses (< 3 mg/kg) but mixed results at high doses (≥ 3 mg/kg). Since this review comprised mostly of single-dose studies and an assortment of methodologies, an empirical dose-ranging study on this topic is warranted.

Objectives: The current study aims to evaluate the conclusion from our systematic review that 3 mg/kg may be the threshold for MDMA-induced amnesia, and to further understand the dose-effect relationship of MDMA on behavioral assays of memory, addiction, and depression.

Methods: We systematically examined the effects of 0.01 to 10 mg/kg MDMA on Pavlovian fear conditioning; behavioral sensitization, conditioned place preference, and conditioned responding; and the Porsolt forced swim test in mice.

Results: High doses of MDMA (≥ 3 mg/kg) produced amnesia of fear conditioning memory, some evidence of an addictive potential, and antidepressant effects, while low doses of MDMA (≤ 1 mg/kg) had no effect on these behaviors.

Conclusions: The present dose-ranging study provides further evidence that 3 mg/kg is the threshold for MDMA-induced amnesia. These findings, in addition to our systematic review, demonstrate that careful selection of MDMA dose is critical. High doses (≥ 3 mg/kg) should likely be avoided due to evidence that they can produce amnesia and addiction. Conversely, there is little evidence to suggest that low doses, which are usually administered in clinical studies (approximately 1-2 mg/kg), will lead to these same adverse effects. Ultra-low doses (< 1 mg/kg) are likely even safer and should be investigated for therapeutic effects in future studies.

Citing Articles

Licit use of illicit drugs for treating depression: the pill and the process.

Torrado Pacheco A, Moghaddam B J Clin Invest. 2025; 134(12).

PMID: 40047885 PMC: 11178541. DOI: 10.1172/JCI180217.


MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).

Shahrour G, Sohail K, Elrais S, Khan M, Javeid J, Samdani K Neuropsychopharmacol Rep. 2024; 44(4):672-681.

PMID: 39381877 PMC: 11609750. DOI: 10.1002/npr2.12485.


Investigating the impact of psychedelic drugs on social cognition defects: A scoping review protocol.

Smith S, Smith S, Dennett L, Zhang Y PLoS One. 2024; 19(7):e0307491.

PMID: 39074107 PMC: 11285908. DOI: 10.1371/journal.pone.0307491.


Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.

Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F CNS Drugs. 2024; 38(10):771-789.

PMID: 39033264 DOI: 10.1007/s40263-024-01101-3.


Sex- and Gender-Specific Drug Abuse Dynamics: The Need for Tailored Therapeutic Approaches.

Marinelli S, Basile G, Manfredini R, Zaami S J Pers Med. 2023; 13(6).

PMID: 37373954 PMC: 10304701. DOI: 10.3390/jpm13060965.


References
1.
Danforth A, Grob C, Struble C, Feduccia A, Walker N, Jerome L . Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl). 2018; 235(11):3137-3148. PMC: 6208958. DOI: 10.1007/s00213-018-5010-9. View

2.
Yazar-Klosinski B, Mithoefer M . Potential Psychiatric Uses for MDMA. Clin Pharmacol Ther. 2016; 101(2):194-196. PMC: 5260336. DOI: 10.1002/cpt.565. View

3.
Hemby S, Jones G, Justice Jr J, Neill D . Conditioned locomotor activity but not conditioned place preference following intra-accumbens infusions of cocaine. Psychopharmacology (Berl). 1992; 106(3):330-6. DOI: 10.1007/BF02245413. View

4.
Robinson T, Berridge K . Addiction. Annu Rev Psychol. 2002; 54:25-53. DOI: 10.1146/annurev.psych.54.101601.145237. View

5.
Shulgin A . The background and chemistry of MDMA. J Psychoactive Drugs. 1986; 18(4):291-304. DOI: 10.1080/02791072.1986.10472361. View